Elysium Cell Bio ITA received the award Le Fonti Awards 2026-

Summer Edition 2026, Milano -Italia

On Thursday, June 25, 2026, in the prestigious setting of Palazzo Mezzanotte, home of the Italian Stock Exchange (Borsa Italiana) in Piazza Affari, Milan, Elysium Cell Bio received the Le Fonti Awards 2026, one of Italy’s most prestigious recognitions honoring excellence in innovation, leadership, and entrepreneurship.

The award recognizes Elysium Cell Bio’s outstanding achievements as an innovative biotechnology company capable of translating cutting-edge biomedical research into tangible healthcare solutions, promoting a model of translational medicine that successfully integrates scientific research, industrial development, and clinical application.

Award Citation

Excellence of the Year – Innovation in Biotechnology and Translational Medicine

For developing an innovative technology transfer model capable of transforming academic research discoveries into products of high scientific and clinical value. For its commitment to precision medicine, the development of nutraceuticals, medical devices, and novel therapeutic strategies based on robust scientific evidence. For its ability to combine research excellence, industrial innovation, intellectual property protection, and an international vision, thereby strengthening the competitiveness of the Italian biotechnology sector and contributing to the improvement of public health.

The True Meaning of the Award

Beyond the recognition itself, this award represents:

• Recognition of the scientific excellence achieved through its research activities.
• Validation of a successful technology transfer model from academia to industry.
• Acknowledgment of Elysium Cell Bio’s capacity to innovate within the biotechnology sector.
• Confirmation of Elysium Cell Bio’s leadership as an example of Italian excellence on the international stage.

The “Heroes” Behind This Achievement

This award belongs to everyone who has contributed to the growth and success of the company:

• Prof. Massimo Zollo, Founder & CEO, for his scientific vision and entrepreneurial leadership.
• Prof. Veronica Ferrucci, Co-founder, for coordinating scientific development and innovation.

• Prof. Vincenzo Diego Bianchi, for his contributions to the treatment of neurodegenerative diseases and cognitive disorders through the Clinica Bianchi in Portici, dedicated to the study and treatment of central nervous system diseases.
• Prof. Roberto Berni Canani, for his clinical and translational contributions.
• Prof. Ivan Gentile, for his expertise and contributions in infectious diseases and translational medicine.
• CEINGE – Advanced Biotechnologies “Franco Salvatore”, for hosting the Elysium Cell Bio Italia laboratories and supporting translational research.
• Dr. Mariano Giustino, Chief Executive Officer of CEINGE.
• Prof. Pietro Forestieri, President of CEINGE.
• Dr. Francesco Pellegrino, expert in pharmaceutical marketing and business development.
• Dr. Pierluigi Gallo, wound care specialist, surgeon, and vulnologist.
• Guacci S.p.A., distributor of Elysium Cell Bio Italia products.
• Polcaro Fitopreparazioni and Aphros Cosmetics, manufacturing partners that embraced and developed the Elysium Cell Bio Italia product lines.
• The researchers, biologists, physicians, pharmacists, and technologists from the University of Naples Federico II and industrial partners whose dedication made this achievement possible.
• The patients and clinicians participating in clinical studies, whose collaboration transforms scientific discoveries into real-world healthcare innovations.

Closing Message

“This award celebrates far more than a company—it celebrates a vision: the belief that Italian scientific research can become innovation, enterprise, and tangible benefits for patients. It recognizes the daily commitment of an entire team united by the conviction that science should improve people’s lives.”

Looking Ahead: Building the Future of Elysium Cell Bio ITA

“This recognition gives us tremendous energy and confirms that the strategic decisions we made at the very beginning of our journey were the right ones,” says *Prof. Massimo Zollo*, Founder & CEO of Elysium Cell Bio ITA.

“Since the establishment of our company in December 2023, we have remained focused on a clear vision: building Elysium Cell Bio ITA into a leading Italian biotechnology brand. Today, this award reinforces our confidence that we are on the right path. We are now entering a new phase of growth, driven by ambitious strategies that will strengthen our scientific leadership, expand our international presence, and accelerate innovation for patients worldwide.”

Our Strategic Priorities

*Expanding Our Market Presence*

We will significantly increase our investment in marketing and brand development to strengthen the visibility of Elysium Cell Bio ITA and bring our innovative products to healthcare professionals and consumers across Italy and international markets.

*Advancing Product Innovation*

We will continue to enhance our portfolio of scientifically validated nutraceuticals while advancing the development of our flagship skin cream toward *Class II Medical Device* certification. At the same time, we will complete the preclinical development of our proprietary small-molecule therapeutic candidate for the treatment of metastatic cancers, including *breast cancer* and *brain tumors*.

*Accelerating International Growth*

We will expand our network of scientific, clinical, and industrial partnerships, with a strategic focus on establishing a strong commercial presence in *Asia* and the *United States*, two of the world’s most dynamic biotechnology and healthcare markets.

*Welcoming Strategic Investors*

Elysium Cell Bio ITA is actively seeking strategic investors and venture capital partners who share our vision of transforming scientific discoveries into innovative healthcare solutions. Additional investment will enable us to accelerate product development, expand internationally, strengthen our intellectual property portfolio, and significantly increase the company’s growth trajectory.

Our Vision

At Elysium Cell Bio ITA, we believe that world-class science should not remain confined to laboratories. Our mission is to transform outstanding research into innovative products and breakthrough therapies that improve patients’ lives while creating sustainable value for our partners, investors, and society.

The journey has only just begun!